Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Boceprevir Triple Therapy in ESRD Patients with Chronic HCV
NCT02112630Withdrawn
- Sponsor
- Columbia University
- Start
- May 2013
- Primary completion
- Feb 2015
- Modality
- Orthosteric Ligands
01
Overview
Open-label trial of boceprevir in hepatitis C (HCV) (2 arms), sponsored by Columbia University. Primary endpoint: Sustained Virologic Response. Planned start May 2013; status: withdrawn.
02
Drugs
boceprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02112630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02112630.